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Abstract 
Background Oral anticoagulation(OAC) is highly effective for stroke prevention in non-valvular 
atrial fibrillation(AF). We explored rates of stroke/thromboembolism/transient ischemic 
attack(TIA) amongst the ‘OAC not recommended’ patient group as defined by the 2014 Canadian 
Cardiovascular Society(CCS) algorithm (based on CHADS2 score) but would have been offered 
OAC using the ESC guidelines approach (based on CHA2DS2-VASc score).      
Methods We identified 22582 non-anticoagulated patients age <65 with a CHADS2=0 who were 
stratified according to the CHA2DS2-VASc score, except female sex, which would be an indication 
for OAC according to the ESC guidelines. Event rates for each risk strata were compared by Cox 
proportional hazard ratios. 
Results   The overall rate of the combined endpoint of ischemic stroke/SE/TIA was 4.32 per 100 
person-years(95%CI 3.26-5.74) at 1 year, amongst the patients who would have had an indication 
for OAC therapy according to ESC guidelines and ‘OAC not recommended’ according to CCS 
algorithm.  This corresponded to an adjusted hazard ratio of 3.08(95%CI 2.21-4.29) relative to the 
subgroup with no indication for OAC by the ESC guidelines.  
A subgroup of patients with prior vascular disease and CHADS2 score=0 (i.e. only recommended 
aspirin treatment according to CCS algorithm) had an event rate of 4.84(95%CI 3.53-6.62) per 100-
person-years at one-year follow-up.     
Conclusion  Based on the 2014 CCS algorithm, the ‘OAC not recommended’ subgroup can have a 
high 1 year stroke rate overall, showing that such patients are not ‘low risk’. Use of the ESC 
guideline approach (based on CHA2DS2-VASc) offers refinement of stroke risk stratification in 
such patients. 
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Brief summary  
We explored the rates of stroke/thromboembolism/transient ischemic attack amongst ‘OAC not 
recommended’ patients as defined by the 2014 Canadian Cardiovascular Society(CCS) algorithm 
(based on CHADS2 score) but would have been offered OAC using the European Society of 
Cardiology guidelines approach (based on CHA2DS2-VASc score). Using the 2014 CCS algorithm, 
the ‘OAC not recommended’ subgroup can have a high 1 year stroke rate of 4.32 per 100 person-
years, suggesting that such patients are not ‘low risk’. 
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Introduction 
Patients with atrial fibrillation (AF) have a five-fold increase in stroke risk, but this risk is not 
homogeneous, and depends on the presence of various stroke risk factors1.  These risk factors have 
been used to derive stroke risk stratification schemes, such as the CHADS2 [congestive heart 
failure, hypertension, age>75 years, diabetes mellitus, stroke (2 points)] score1.  When the only 
available oral anticoagulant was the Vitamin K Antagonist class of drugs (VKA, e.g. warfarin), 
these schemes were used to identify ‘high risk’ patients, who could be targeted for warfarin therapy. 
With the availability of NOACs and better management of VKAs, the focus of many guidelines 
(European Society of Cardiology (ESC), National Institute for Health and Care Excellence (NICE)) 
now is to initially identify ‘low risk’ patients who do not need any antithrombotic therapy2 3. 
Subsequent to this step, patients with ≥1 additional stroke risk factors can be offered effective 
stroke prevention, which is a NOAC or well-managed VKA (with time in therapeutic range >65-
70%). The CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, 
age>75 years (2 points), diabetes mellitus, stroke (2 points), vascular disease, age 65–75 years, and 
female sex)] score was introduced as a simple clinical risk score that reliably identifies those at ‘low 
risk’ (ie. CHA2DS2-VASc score=0 (male) or 1 (female)) of stroke and thromboembolism4.   
In 2014, the Canadian Cardiovascular Society (CCS) published its focused update guideline 
offering a simplified algorithm-based approach to stroke risk stratification5. The first step in the 
algorithm was to identify those ‘age ≥65’ who should be offered OAC. The second step is to 
identify those age<65 with CHADS2 risk factors (heart failure, hypertension, diabetes or 
stroke/TIA), who should have OAC. Next, those age<65 who are ‘CHADS2 score=0 with ‘arterial 
disease i.e. coronary, aortic or peripheral’ are recommended aspirin alone (and not OAC). Finally, 
those patients age<65 with no CHADS2 risk factors nor vascular disease are recommended ‘no 
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antithrombotic therapy’5. The 2014 CCS guideline text states that ‘We do not consider female sex 
or vascular disease alone as sufficient reasons to prescribe OAC therapy.’ 
In this analysis of non-anticoagulated patients from the Danish nationwide cohort study, we 
explored the rates of stroke/thromboembolism/TIA amongst the ‘OAC not recommended’ patient 
group as defined by the 2014 CCS algorithm (based on the CHADS2 score) stratified according to 
OAC recommendation using the ESC guidelines (based on the CHA2DS2-VASc score). We tested 
the hypothesis that the ‘OAC not recommended’ patient group using the 2014 CCS algorithm could 
have further refinement of stroke risk stratification by using the ESC guidelines approach. 
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Methods 
 
The detailed methods of the Danish registries have been previously described6.  In brief, based on 
the Danish National Patient Register and the Danish National Prescription Registry we identified all 
incident hospital or ambulatory diagnoses of nonvalvular AF in the study period from 1999 to 2012. 
Nonvalvular AF was defined as presence of atrial fibrillation (ICD10: I48), and baseline absence of 
mitral stenosis or mechanical heart valves (ICD10: I05 or Z952-Z954). All patients were without 
VKA prescription at least one year prior to AF diagnose. As a measure of ‘non-treatment with 
VKA’, we used person-time off VKA treatment. Patients only contributed with person-time until a 
prescription of VKA was claimed (if any). The CHADS2 and CHA2DS2-VASc scores were 
ascertained from the Danish registries as previously described6.  The CHADS2 score was 
ascertained by including diagnosis on congestive heart failure, hypertension, age, diabetes mellitus 
and presence of previous stroke/transient ischemic attack.  The CHA2DS2-VASc score was 
calculated by including diagnosis on congestive heart failure/left ventricular dysfunction, 
hypertension, age, diabetes mellitus, female sex, vascular disease and presence of previous 
stroke/thromboembolism/transient ischemic attack; the detailed outline of the utilised ICD-10 
diagnosis and concomitant medication is provided in supplementary Table 1.  Thus, the CHA2DS2-
VASc would include congestive heart failure (like CHADS2, but also specifying recent 
decompensated heart failure, with reduced or preserved ejection fraction) and moderate-severe LV 
dysfunction on cardiac imaging (even if asymptomatic)2. 
As our focus was the ‘OAC not recommended’ patient group as defined by the 2014 CCS 
algorithm5 in relation to the ESC guidelines (based on the CHA2DS2-VASc score), we restricted the 
study population to patients with age below 65 years and with a CHADS2 score of zero.  The main 
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outcome was stroke/thromboembolism and defined as a combined end point of ischemic stroke, 
systemic embolism (SE), and transient ischemic attack (TIA) (ICD-10: I63; I64, G45; I74). Person-
time was censored if patients died, if a prescription of a VKA was claimed during follow-up, at 
emigration or end of follow-up, whichever came first.  Secondary analyses investigated the 
outcomes of (extra cranial) major bleeding (ICD-10: D62; J942; H113; H356; H431; N02; N95; 
R04; R31; R58) and intracranial haemorrhage (ICD-10: I60; I61; I62), to indicate the bleeding risk 
of this cohort, as ultimately decisions on antithrombotic therapy would be based on the balance 
between stroke and serious bleeding risks. Two sensitivity analyses were performed, as follows: (i) 
we confined our primary endpoint analysis to ischemic stroke/SE, and (ii) we investigated a 
combined endpoint of ischemic stroke/haemorrhagic stroke/SE to ascertain if the benefit from 
stroke prophylaxis could offset by the risk of intracranial haemorrhage.  
 
Event rates of stroke/thromboembolism per 100 person-years were calculated for the patient groups 
defined by whether there was an indication for OAC therapy according to ESC guidelines, i.e. a 
CHA2DS2-VASc score ≥1 (males) or ≥2 (females). A Cox proportional hazard analysis was 
constructed to inspect the risk related to treatment indication to ascertain if patients with a 
CHA2DS2-VASc score ≥1 (males) or ≥2 (females) were at greater risk of stroke/thromboembolism 
compared to those not indicated for treatment (i.e. CHA2DS2-VASc score =0 (males) or 1 (females), 
based on ESC guidelines). We performed both unadjusted and adjusted analyses (adjusted for 
baseline ASA use and year of inclusion, in a categorical manner). All analyses were reported for a 
1-year follow-up. 
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Results 
The study population comprised 22582 AF patients age <65 with a CHADS2 score of zero; 1731 
patients had indication for OAC treatment according to the ESC guidelines, see Table 1.  A 
breakdown of what factors in the CHA2DS2-VASc score that led to their classification as 
'anticoagulation indicated' (n=1731) consisted of n=54 with systemic embolism (35% females; 28% 
aspirin use), n=1149 with vascular disease (26% female; 38% aspirin use) and n=695 with left 
ventricular dysfunction (22% female; 11% aspirin use). 
The overall rate of the combined endpoint of ischemic stroke/SE/TIA was 4.32 per 100 person-
years (95%CI 3.26-5.74) at 1 year, amongst patients who would have had indication for OAC 
therapy according to ESC guidelines [Table 2].  In contrast, the subjects with no indication for OAC 
according to the ESC guideline criteria had an ischemic stroke/SE/TIA event rate of 1.13 per 100 
person-years.   
When compared to those with no indication for OAC by the ESC guidelines, an unadjusted and 
adjusted analysis (adjusting for baseline aspirin use and year of inclusion) showed hazard ratios of 
3.60 (95%CI 2.62-4.94) and 3.08 (95%CI 2.21-4.29), respectively for ischemic stroke/SE/TIA in 
patients who by ESC guidelines had an indication for treatment.  
Sensitivity analyses 
A sensitivity analysis confining our combined endpoint to ‘ischemic stroke/SE’ did not change our 
conclusions, with event rates of 3.96 per 100 person-years (95%CI 2.95-5.32) for patients with 
indication for OAC treatment and 0.94 (95%CI 0.80-1.10) for patients with no indication for OAC 
treatment, according to the ESC guideline criteria.   
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Investigating the combined endpoint of ‘both ischemic and haemorrhagic stroke, and SE’ showed 
consistent result of event rates being higher in the group with indication for OAC treatment 
(according to the ESC guideline criteria) compared to those no indication for OAC, that is, 4.14 
(95%CI 3.10-5.53) vs 1.15 (95%CI 1.00-1.33) per 100 person-years, respectively. 
Subgroup and secondary analyses 
Analysing the subgroup of patients with vascular disease (n=1149) who by CCS guidelines would 
not require OAC treatment (i.e. presence of vascular disease and CHADS2 score=0), the 
stroke/SE/TIA rate was 4.84 (95%CI 3.53-6.62) for one year follow-up.  
In this subgroup of AF patients with vascular disease, the event rates per 100 person-years for males 
and females were 4.53 (95%CI 3.11-6.61; 27 events) and 5.69 (95%CI 3.23-10.01; 12 events), 
respectively; also, the adjusted hazard ratio for sex for the full follow-up period showed an increase 
in hazard ratio for female sex, 1.74 (95%CI 1.06-2.86). 
Secondary analyses on major bleeding (extra cranial) and intracranial haemorrhage events showed 
low event rates in the group with an indication for OAC therapy according to ESC guidelines, of 
1.26 (95%CI 0.74-2.12) and 0.25 (95%CI 0.13-0.95), respectively.  
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Discussion 
In this analysis we show that based on the 2014 CCS algorithm, the ‘OAC not recommended’ 
subgroup can have a 1-year stroke rate overall of 4.32 per 100-patient years, showing that such 
patients are not ‘low risk’. Indeed, vascular disease and female sex should not be ignored when 
undertaking stroke risk stratification of AF patients.  Thus, the ‘OAC not recommended’ patient 
group based on the 2014 CCS guidelines could have further refinement of stroke risk stratification 
by using the ESC guidelines approach.   
Decisions on thromboprophylaxis require a balance between stroke and bleeding risks, and in 
patients with >1 additional stroke risk factors, the net clinical benefit balancing stroke, mortality 
and serious bleeding is usually in favour of OAC use.7, 8  With the availability of NOACs that offer 
relative efficacy, safety and convenience compared to the VKAs, Eckman et al9 have even 
estimated that the ‘tipping point’ threshold for OAC treatment may be a stroke rate of ≥0.9%/year.  
Indeed, secondary analyses shows that our patient group was also at low risk of major bleeding or 
ICH10. Thus, our data support the approach in the ESC and NICE guidelines that advocates a 
clinical practice shift towards the initial step of identifying ‘truly low risk’ patients (who do not 
need any antithrombotic therapy), using the CHA2DS2-VASc score. Subsequent to that step, 
effective stroke prevention (which is OAC, whether a NOAC or well-controlled warfarin) can then 
be offered to those with ≥1 additional stroke risk factors11. 
Vascular disease is also an independent predictor of stroke risk. In a recent systematic review, 
vascular disease was clearly contributory to an increased stroke risk12. This may be particularly 
evident in Asians, where 1.8 fold increase in stroke risk was seen on multivariable analysis13 
compared to Europeans, where (for example) a 1.22 fold increase was reported in the Swedish AF 
cohort study (with similar adjusted relative hazard to hypertension and diabetes mellitus)14 and 1.12 
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fold in the Danish cohort15.  Thus, vascular disease should be included when undertaking stroke risk 
stratification of AF patients.   
When males and females with ‘CHADS2=0 plus vascular disease’ were compared, stroke rates were 
higher in the female patients, with a hazard ratio of 1.74.  Thus, our data suggest that female AF 
patients age <65 with vascular disease represent a high stroke risk subgroup; however, the 2014 
CCS algorithm does not recommend OAC in this population. Our data are consistent with a recent 
systematic review and meta-analysis showing female sex as a risk factor, regardless of OAC use 
[Risk Ratio (95%CI 1.29(1.09-1.52) and 1.49(1.17-1.90) in non-anticoagulated vs. anticoagulated/ 
mixed cohorts, respectively)16.  Thus, female sex should not be ignored when undertaking stroke 
risk stratification of AF patients, but would only be relevant with ≥1 additional stroke risk factors.   
Indeed, females with a CHA2DS2-VASc score=1 by virtue of their sex alone are ‘low risk’17.  
Limitations 
The limitations of this nationwide cohort study are well recognized by us, especially its 
observational, non-randomised design where residual confounding may be evident6. Nonetheless, 
our data urge caution such that vascular disease should not be ignored when undertaking stroke risk 
stratification of AF patients, when considering patients for OAC. As reflected by the small decrease 
in the analysis adjusted for baseline aspirin treatment, aspirin is minimally effective for stroke 
prevention in AF, and not safe nor cost-effective3.  
 
In conclusion, based on the 2014 CCS algorithm, the ‘OAC not recommended’ subgroup can still 
have a high stroke rate overall. Such patients are not ‘low risk’, and should be considered for OAC.      
Use of the ESC guideline approach (based on the CHA2DS2-VASc score) would allow refinement 
of stroke risk stratification in such patients.  
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Table 1: Baseline characteristics for non-anticoagulated atrial fibrillation patients age <65 
with a CHADS2 score of zero (‘OAC not recommended’ as defined by the 2014 CCS 
algorithm) 
 
 
No indication for 
OAC treatment 
Indication for OAC treatment 
based on the ESC guidelines 
N (%) n=20,851 (92.3) n=1,731 (7.7) 
Age, mean (IQR) 55.5 (47.0 – 60.7) 58.9 (53.5 – 62.1) 
Female sex 7,505 (36.0) 428 (24.7) 
Previous systemic embolism 0 54 (3.1) 
Prior vascular disease 0 1149 (66.4) 
Prior left ventricular 
dysfunction 
0 695 (40.2) 
Aspirin 2,151 (10.3) 473 (27.3) 
Clopidogrel  66 (0.3) 92 (5.3) 
Dipyridamole 92 (0.4) 95 (5.5) 
CHA2DS2VASc score 
  
Male=0 / female=1 20,851 0 
1 (males) 0 1,179 (68.1) 
2 0 479 (27.7) 
3 0 51 (2.9) 
4 0 20 (1.2) 
5 0 2 (0.1) 
 
CCS, Canadian Cardiovascular Society; ESC, European Society of Cardiology 
CHADS2 and CHA2DS2-VASc, see text 
OAC, oral anticoagulation
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16
Table 2: Event rates for ischemic stroke/SE/TIA stratified on indication for OAC treatment 
according to the ESC guidelines. 
  One year follow-up   
 N Person-
years 
Events Event rate 
(95% CI) 
Crude HR 
(95% CI) 
Adjusted HR 
(95% CI) 
No indication for 
treatment 
20,851 16,278 184 1.13  
(0.98-1.31) 
Ref Ref 
Indication for 
OAC treatment 
1,731 1,110 48 4.32  
(3.26-5.74) 
3.60  
(2.61-4.94) 
3.08  
(2.21-4.29) 
 
Ref=Reference 
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Supplementary Table 1 
 
 
International Classification of 
Diseases 10th revision (ICD-10) 
code 
Anatomical Therapeutic Chemical 
(ATC) code 
Condition   
  Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C 
  Left ventricular dysfunction I50.1; I50.9  
  Hypertension  See specified definition* 
  Diabetes mellitus E10.0; E10.1; E10.9; E11.0; E11.1; 
E11.9 
A10 
  Ischemic stroke I63; I64  
  Systemic embolism I74  
  Transient ischemic disease G45  
  Aortic plaque I70.0  
  Peripheral arterial disease  I70.2-I70.9; I71; I73.9; I74  
  Myocardial infarction I21-I23  
  Nonvalvular atrial fibrillation I48 and baseline absence of I05 
and Z952, Z953, Z954 
 
  Extra cranial major bleeding D62 J942 H113 H356 H431 N02 
N95 R04 R31 R58 
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  Intracranial bleeding 
  Traumatic intracranial bleeding 
  Retinal bleeding 
I60 I61 I62 
S063C S064 S065 S066 
H356 
 
Medication 
 
 
  Warfarin  B01AA03 
  Aspirin/Clopidogrel  B01AC06/B01AC04 
  Dipyridamole 
 
B01AC07 
 
* We identified subjects with hypertension from combination treatment with at least two of the following classes of 
antihypertensive Drugs: 
I. Alpha adrenergic blockers (C02A, C02B, C02C) 
II. Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, 
C09XA52) 
III. Vasodilators (C02DB, C02DD, C02DG, C04, C05)  
IV. Beta blockers (C07) 
V. Calcium channel blockers (C07F, C08, C09BB, C09DB) 
VI. Renin-angiotensin system inhibitors (C09). 
 
